Beyond Autologous: Why China’s Allogeneic CAR-T Pipeline Deserves European Attention Now
SEQOVA Biotech Insights | May 2026 The approved CAR-T therapies that reshaped haematological oncology over the past decade were all
Beyond Autologous: Why China’s Allogeneic CAR-T Pipeline Deserves European Attention Now Read More »
Why Good Assets Don’t Close: The Hidden Weight of Execution
You can usually tell where a deal is going to get difficult. Not at the beginning. That part usually moves
Why Good Assets Don’t Close: The Hidden Weight of Execution Read More »
Radiopharmaceuticals 2025–2026: Why Cost, Infrastructure, and Workflow Now Matter More Than Novelty
Radiopharmaceuticals innovation in 2026 have moved decisively beyond their historical niche in nuclear medicine. What was once a specialised diagnostic
LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026
Interest in long-acting injectables (LAIs) for Central Nervous System (CNS) disorders has returned to business development and investment discussions for
LAI Licensing in Central Nervous System Disorders: Where Execution Risk Sits in 2026 Read More »
Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning
For years, inhalation drug licensing has been misunderstood. It wasn’t deprioritized because it failed scientifically. It was deprioritized because the
Inhalation Drug Licensing in 2026: Why Execution-Ready Assets Are Queitly Winning Read More »
Computerized System Validation (CSV) in Pharma: 2025 Updates and Preparing for 2026 Compliance
Computerized System Validation (CSV) is no longer a static compliance exercise. In 2025, regulators made that clear. Both the EMA
AI in Biotech Manufacturing: Where Value Is Real and Where GMP Caution Is Essential
AI Has Moved From Experiment to Infrastructure In 2025, artificial intelligence (AI) is no longer confined to innovation labs or
AI in Biotech Manufacturing: Where Value Is Real and Where GMP Caution Is Essential Read More »
Building Bridges, Not Just Deals: How SEQOVA Cross-Border Partnerships Are Shaping the Future of Pharma
In today’s pharma landscape, cross-border collaboration is no longer optional, it’s essential. From biotech startups seeking validation partners to established
Mergers and Acquisitions in the Pharma Industry: A Strategic Imperative
Pharma M&A trends, key drivers, and top 2023–2024 deals A Structural Pillar of Pharma Strategy: Mergers and Acquisitions Mergers and
Mergers and Acquisitions in the Pharma Industry: A Strategic Imperative Read More »